LinkedIn

 آمار

تعداد نشریات21
تعداد شماره‌ها1,287
تعداد مقالات11,774
تعداد مشاهده مقاله82,958,432
تعداد دریافت فایل اصل مقاله121,798,140
Ansari, Ramin, Vazin, Afsaneh, Hosseini, Mahnaz Sadat, Afarin, Behrad. (1405). An Update on Pharmacological and Clinical Aspects of S-adenosylmethionine in Metabolic Syndrome. سامانه مدیریت نشریات علمی, 12(2), -. doi: 10.30476/tips.2026.109859.1338
Ramin Ansari; Afsaneh Vazin; Mahnaz Sadat Hosseini; Behrad Afarin. "An Update on Pharmacological and Clinical Aspects of S-adenosylmethionine in Metabolic Syndrome". سامانه مدیریت نشریات علمی, 12, 2, 1405, -. doi: 10.30476/tips.2026.109859.1338
Ansari, Ramin, Vazin, Afsaneh, Hosseini, Mahnaz Sadat, Afarin, Behrad. (1405). 'An Update on Pharmacological and Clinical Aspects of S-adenosylmethionine in Metabolic Syndrome', سامانه مدیریت نشریات علمی, 12(2), pp. -. doi: 10.30476/tips.2026.109859.1338
Ansari, Ramin, Vazin, Afsaneh, Hosseini, Mahnaz Sadat, Afarin, Behrad. An Update on Pharmacological and Clinical Aspects of S-adenosylmethionine in Metabolic Syndrome. سامانه مدیریت نشریات علمی, 1405; 12(2): -. doi: 10.30476/tips.2026.109859.1338

An Update on Pharmacological and Clinical Aspects of S-adenosylmethionine in Metabolic Syndrome

Trends in Pharmaceutical Sciences and Technologies
دوره 12، شماره 2، شهریور 2026
نوع مقاله: Review Article
شناسه دیجیتال (DOI): 10.30476/tips.2026.109859.1338
نویسندگان
Ramin Ansari1؛ Afsaneh Vazin* 1؛ Mahnaz Sadat Hosseini2؛ Behrad Afarin3
1Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
2Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
3School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
چکیده
Abstract
S-adenosylmethionine (SAMe), recognized as the principal methyl donor in metabolic reactions, has recently attracted growing research interest. It has been investigated as a potential biomarker for cardiovascular diseases and various malignancies. Although SAMe supplements have been available for more than five decades, evidence supporting their clinical efficacy across most proposed indications remains limited. Given the global impact of metabolic syndrome, this study aims to review current evidence regarding the role of SAMe in its pathophysiology.
Relevant studies assessing the association between SAMe and metabolic syndrome in humans or animal models were identified through searches of Scopus, PubMed, and Google Scholar databases from beginning to 2025, following standard narrative review methodology.
Approximately 50 relevant publications were identified, addressing the relationship between SAMe levels and coronary artery disease, besides the effect of SAMe supplementation and hypertension, ischemia, aortic dissection, obesity, diabetes, heart failure, myocardial infarction, and liver disorders such as metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, cholestasis, jaundice, and viral hepatitis.
Findings on the therapeutic role of SAMe supplementation remain limited and often contradictory. As both SAMe deficiency and excess appear to contribute to the development of metabolic syndrome, further research exploring its dose-dependent effects is essential.
کلیدواژه‌ها
S-adenosylmethionine؛ Metabolic Syndrome؛ Cardiovascular؛ MASH؛ Diabetes
آمار
تعداد مشاهده مقاله: 8


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب